Prestige Consumer Healthcare (PBH) Barclays 17th Annual Global Consumer Staples Conference summary
Event summary combining transcript, slides, and related documents.
Barclays 17th Annual Global Consumer Staples Conference summary
22 Jan, 2026Brand portfolio and category insights
Operates in women's health, cough/cold, GI, and ear/eye care, focusing on unique brand positioning rather than broad categories.
Key brands include Monistat, Summer's Eve, Clear Eyes, TheraTears, and Debrox, each serving distinct consumer needs.
Summer's Eve repositioning toward beauty/daily hygiene was less successful, but Monistat and eye care brands show stable growth.
GI brands like Dramamine and Gaviscon are performing well, with ongoing product innovation.
Growth profile and business evolution
Shifted from household cleaning to a focused consumer healthcare portfolio since 2010, with major acquisitions and divestitures.
Achieved 2%-3% organic CAGR over the past five years, supported by innovation and changing consumer habits post-COVID.
Growth during inflation was driven mostly by price, not volume loss, differentiating from other CPGs.
Competitive landscape and category growth
Peers with broader geographic reach or beauty/personal care focus may achieve higher growth rates.
International business expected to grow 5%-6% long-term, with eye care as a key North American growth driver.
Eye care growth fueled by increased screen time and greater consumer awareness of dry eye treatment.
Latest events from Prestige Consumer Healthcare
- Q3 revenue fell 2.4% but cash flow and Pillar5 acquisition supported a confident outlook.PBH
Q3 20268 Jul 2026 - Record revenue, EPS, and cash flow growth set the stage for continued gains in fiscal 2026.PBH
Q4 20258 Jul 2026 - Strong free cash flow and strategic acquisitions drive value amid robust governance and ESG focus.PBH
Proxy filing29 Jun 2026 - Major acquisitions and disciplined strategy position for strong growth and international expansion.PBH
Oppenheimer 26th Annual Consumer Growth and E-Commerce Conference8 Jun 2026 - Fiscal 2026 revenue fell 4.3%, but 2027 targets growth, margin stability, and accretive M&A.PBH
Q4 202614 May 2026 - $1.045B acquisition of a top nasal strip brand boosts growth, margins, and global scale.PBH
M&A announcement23 Mar 2026 - Q1 revenue beat expectations, cash flow rose, and FY2025 outlook was reaffirmed.PBH
Q1 20252 Feb 2026 - Brand investment, innovation, and disciplined capital allocation drive growth amid supply chain recovery.PBH
Oppenheimer's 24th Annual Virtual Consumer Growth and E-Commerce Conference1 Feb 2026 - Brand innovation, e-commerce growth, and strong cash flow drive long-term value creation.PBH
Sidoti September Small-Cap Virtual Conference20 Jan 2026